Coherus Expects Q2 FY23 Sales Of At Least $48M-$53M From Udenyca And Cimerli; For FY23 It Projects Over $275M, Including At Least $100M From Cimerli, With The Balance Comprising Net Sales Of Udenyca, Yusimry And Toripalimab
Portfolio Pulse from Benzinga Newsdesk
Coherus expects Q2 FY23 sales of $48M-$53M from Udenyca and Cimerli, and over $275M for FY23, including at least $100M from Cimerli. The company affirms prior guidance for full year 2023 combined R&D and SG&A expenses in the range of $315M-$335M.
June 16, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus expects strong Q2 FY23 sales from Udenyca and Cimerli, and maintains prior guidance for 2023 R&D and SG&A expenses.
The news highlights Coherus' positive sales expectations for Q2 FY23 and the full year, driven by Udenyca and Cimerli. This is likely to boost investor confidence and have a positive short-term impact on the stock price. The company's affirmation of prior guidance for 2023 R&D and SG&A expenses also indicates stability in its financial planning.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100